- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00607230
Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics
November 4, 2013 updated by: David M. Nathan, MD, Massachusetts General Hospital
Determination of Dosing and Frequency of BCG Administration Necessary to Alter T-Lymphocyte Profiles in Type I Diabetics
Type 1 diabetes is caused by an autoimmune destruction of the insulin producing cells of the pancreas.
The investigators have discovered the specific autoimmune cells responsible for destroying the insulin-producing cells in an animal model of type 1 diabetes, and the means of destroying those cells.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The investigators are now aiming to use a similar strategy (vaccination with BCG, the vaccine used world-wide to protect against tuberculosis) in human type 1 diabetes to see if the abnormal immune cells can be depleted.
This is the first step in trying to cure established type 1 diabetes.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Diabetes Research Center at Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria (Type 1 diabetic subjects):
- Type 1 diabetes treated continuously with insulin from time of diagnosis
- Age 18-55
- Anti-GAD positive
- HIV antibody negative
- Normal CBC
- Negative intermediate PPD test performed and read by study staff
- HCG Negative (females)
Exclusion Criteria Type 1 diabetic subjects):
- History of chronic infectious disease, such as HIV
- History of tuberculosis, TB risk factors, or history of + PPD, or BCG vaccination
- Treatment with glucocorticoids (other than intermittent nasal steroids) or disease or condition likely to require steroid therapy
- Other conditions or treatments associated with increased risk of infections such as patients with previous history of severe burns, or treatment with immunosuppressive medications of any type (e.g. imuran, methotrexate, cyclosporine, etanercept, infliximab) for any reason
- Current treatment with aspirin > 160 mg/day or chronic, daily NSAIDs
- Fasting or stimulated (1 mg glucagon stimulation test) c-peptide > 0.2 pmol/mL
- History of keloid formation
- HbA1c > 8.0%
- History or evidence of chronic kidney disease (serum creatinine > 1.5 mg/dL)
- History of proliferative diabetic retinopathy that has not been treated with laser therapy
- Pregnant or not using acceptable birth control
- Living with someone who is immunosuppressed and/or at high risk for infectious diseases (for example HIV+ or taking immunosuppressive medications for any reason).
Inclusion Criteria (Control Non-diabetic Subjects):
- Age 18-45
Exclusion Criteria (Control Non-diabetic Subjects):
- History of autoimmune diseases or diabetes
- History of HIV History of autoimmune disease or type 1 diabetes (use of insulin continuously since diagnosis) in first degree family members
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: E
BCG vaccination
|
BCG vaccination at 0 and 4 weeks
|
Placebo Comparator: P
Saline vaccination
|
Saline vaccination at 0 and 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
concentration of autoreactive t-cells
Time Frame: Measured weekly in first 8 weeks, then every other week for weeks 8-12
|
Measured weekly in first 8 weeks, then every other week for weeks 8-12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Concentration of TNF, TNF-receptors, other cytokines, and c-peptide levels
Time Frame: Weekly for first 8 weeks, then every other week for weeks 8-12
|
Weekly for first 8 weeks, then every other week for weeks 8-12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2007
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
February 1, 2011
Study Registration Dates
First Submitted
January 22, 2008
First Submitted That Met QC Criteria
February 4, 2008
First Posted (Estimate)
February 5, 2008
Study Record Updates
Last Update Posted (Estimate)
November 5, 2013
Last Update Submitted That Met QC Criteria
November 4, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2007p-001347
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on BCG
-
Bandim Health ProjectUniversity of Southern DenmarkRecruitingMorbidity;Newborn | Non-specific Effects of Vaccines | Death, Infant | Morbidity;Infant | Death; NeonatalGuinea-Bissau
-
Bandim Health ProjectOdense University Hospital; Odense Patient Data Explorative Network; Municipality...CompletedCovid19 | Immunosenescence | Vaccine Preventable Disease | Morbidity | Non-specific Effects of Vaccines | Heterologous ImmunityDenmark
-
AerasUniversity of RochesterCompleted
-
Bandim Health ProjectResearch Center for Vitamins and Vaccines, Statens Serum InstituteTerminatedInfant Mortality | BCGGuinea-Bissau
-
ImmunityBio, Inc.RecruitingNon-muscle Invasive Bladder CancerUnited States
-
Murdoch Childrens Research InstituteRoyal Children's Hospital; University of Melbourne; Mercy Hospital for Women,...Active, not recruitingRespiratory Tract Infections | Allergy | EczemaAustralia
-
Biofabri, S.LSouth African Tuberculosis Vaccine Initiative; TuBerculosis Vaccine Initiative and other collaboratorsCompletedTuberculosisSouth Africa
-
Bandim Health ProjectResearch Center for Vitamins and VaccinesCompletedVaccine Adverse Reaction | Vaccine Reaction | Infant Mortality | Heterologous Immunity | Infant Morbidity | Trained ImmunityGuinea-Bissau
-
Chengdu CoenBiotech Co., LtdHunan Cancer HospitalCompleted
-
Chengdu CoenBiotech Co., LtdSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting